Effect comparison of domestic Rapamycin and Ivermus or Zotamos drugeluting stents in the treatment of left main coronary artery opening and body lesions
WANG Zhi-chao LI Xiao-long CHEN Yu CAO Yi QIU Yi-gang XU Zheng-ming LI Tian-chang▲
Department of Cardiovascular Medicine, the Sixth Medical Center of PLA General Hospital, Beijing 100089, China
Abstract：Objective To compare the effect of domestic Rapamycin and Ivermus or Zotamos drug-eluting stents in the treatment of left main coronary artery opening and body lesions.Methods All of 44 patients with left main coronary artery ostium and body lesions treated with drug-eluting stent in our hospital from May 2014 to December 2015 were selected as the study subjects, according to the type of stents, they were divided into domestic Rapamycin drug-eluting stents group (Rapamycin stent group, FIREWARK, NANO, n=16) and Ivermus or Zotamos drug-eluting stents group(Ivermus, Zotamos stent group, n=28) and patients were followed-up and observed.The incidence of cardiogenic death(death without definite other causes) and target vessel revascularization were compared between the two groups.Results All patients were followed up for an average of 33 months.The incidence of events was 6.25% in Rapamycin stent group and 7.14% in Everolimus and Zotamos stent group.There was no significant difference in the incidence of events between the two groups (χ2=0.010, P=0.922).Conclusion The effect of domestic Rapamycin drug-eluting stents in the treatment of left main opening and body lesions is not inferior to that of Ivermus or Zotamos drug-eluting stents.
王志超；李小龙；陈宇；曹毅；裘毅刚；徐争鸣；李田昌. 国产雷帕霉素与依维莫司或佐他莫司药物洗脱支架治疗冠状动脉左主干开口及体部病变效果比较[J]. 中国当代医药, 2019, 26(15): 51-53转57.
WANG Zhi-chao； LI Xiao-long ；CHEN Yu ；CAO Yi ；QIU Yi-gang； XU Zheng-ming； LI Tian-chang. Effect comparison of domestic Rapamycin and Ivermus or Zotamos drugeluting stents in the treatment of left main coronary artery opening and body lesions. 中国当代医药, 2019, 26(15): 51-53转57.
京公网安备 11010502046607号